Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ: DCPH )

25.59 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
DCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
DCPH stock results show that Deciphera Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
Via Benzinga
What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
Via Benzinga
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc.... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug discovery, commercial platforms, and a pipeline of cancer drugs including... 
Via Benzinga
Earnings Preview: Deciphera Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
Via Benzinga
Recap: Deciphera Pharmaceuticals Q1 Earnings
Via Benzinga
Preview: Deciphera Pharmaceuticals's Earnings
Via Benzinga
Crude Oil Down Over 1%; Deciphera Pharmaceuticals Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why Is Mullen Automotive (MULN) Stock Up 27% Today?
Mullen Automotive stock is climbing higher on Monday with heavy trading of MULN shares alongside it joining a new voucher program. 
Via InvestorPlace
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Via Benzinga
Citi Just Raised Its Price Target on Shopify (SHOP) Stock
Shopify stock is on the rise Monday as shares of SHOP got an increased price target and an upgrade from Citi's analysts this morning. 
Via InvestorPlace
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
Deciphera Pharmaceuticals stock is up on Monday after DCPH investors learned of a $2.4 billion acquisition deal with ONO Pharmaceutical. 
Via InvestorPlace
Dow Surges Over 100 Points; Domino's Pizza Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion
The company is working on cancer treatments that block problematic kinases by targeting their switch-control pocket. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT)  
Via Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing. 
Via InvestorPlace
3 Under-the-Radar Biotech Stocks to Buy in 2023
All three biotech companies focus on oncology therapies. 
Via The Motley Fool
Why Shares of Deciphera Pharmaceuticals Rose This Week
The company's shares rose after the company reported second-quarter earnings. 
Via The Motley Fool
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.